Impact of Intraoperative Intravenous Lidocaine Administered During Laparoscopic Colorectal Surgery on Remifentanil Consumption, Postoperative Pain and Immune Cell Activity: A Pilot Study
Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ASA status I, II or III
• Patients older than 18 years
• Colonic surgery
• Classical management of ERAS program patients in our center
Locations
Other Locations
Canada
Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal
RECRUITING
Montreal
Contact Information
Primary
Philippe Richebé, MD PhD
philippe.richebe@umontreal.ca
514-743-6558
Backup
Nadia Godin, RN
ngodin.hmr@ssss.gouv.qc.ca
514-525-3400
Time Frame
Start Date: 2019-04-29
Estimated Completion Date: 2025-06
Participants
Target number of participants: 60
Treatments
Experimental: intravenous lidocaine (IVL)
Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
Placebo_comparator: Placebo
Will receive the same volume of normal saline for the entire duration of anesthesia.
Related Therapeutic Areas
Sponsors
Collaborators: Foundation of Anesthesia and Resuscitation of Quebec
Leads: Ciusss de L'Est de l'Île de Montréal